Brokerages Set Medpace Holdings, Inc. (NASDAQ:MEDP) Price Target at $490.82

Medpace Holdings, Inc. (NASDAQ:MEDP) has been assigned an average rating of “Hold” from the seventeen research firms that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $490.8182.

Several equities research analysts recently issued reports on the company. BMO Capital Markets assumed coverage on Medpace in a research note on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price target for the company. Barclays lifted their price objective on Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a report on Monday, December 15th. TD Cowen upped their target price on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research report on Friday, October 24th. Rothschild & Co Redburn cut Medpace from a “buy” rating to a “neutral” rating and raised their price target for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Finally, Truist Financial set a $555.00 price target on Medpace in a research note on Monday, October 27th.

Medpace Price Performance

MEDP stock opened at $568.85 on Friday. Medpace has a fifty-two week low of $250.05 and a fifty-two week high of $626.26. The stock has a market capitalization of $16.02 billion, a price-to-earnings ratio of 39.78, a PEG ratio of 2.15 and a beta of 1.43. The business’s fifty day moving average price is $580.59 and its two-hundred day moving average price is $486.43.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same period in the prior year, the company posted $3.01 earnings per share. Medpace’s revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Research analysts expect that Medpace will post 12.29 EPS for the current year.

Insider Activity

In related news, President Jesse J. Geiger sold 21,503 shares of Medpace stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total value of $12,808,476.98. Following the transaction, the president directly owned 15,000 shares of the company’s stock, valued at $8,934,900. This trade represents a 58.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This represents a 42.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 387,925 shares of company stock worth $233,386,647. 20.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Medpace

A number of large investors have recently modified their holdings of the business. Hsbc Holdings PLC raised its holdings in shares of Medpace by 157.5% during the 1st quarter. Hsbc Holdings PLC now owns 4,364 shares of the company’s stock worth $1,296,000 after buying an additional 2,669 shares in the last quarter. OMERS ADMINISTRATION Corp grew its position in Medpace by 39.6% in the first quarter. OMERS ADMINISTRATION Corp now owns 6,074 shares of the company’s stock valued at $1,851,000 after acquiring an additional 1,724 shares during the last quarter. State of Wyoming raised its stake in Medpace by 24.6% during the first quarter. State of Wyoming now owns 365 shares of the company’s stock worth $111,000 after acquiring an additional 72 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in Medpace by 9.0% during the first quarter. Canada Pension Plan Investment Board now owns 47,400 shares of the company’s stock worth $14,442,000 after acquiring an additional 3,900 shares in the last quarter. Finally, Magnetar Financial LLC bought a new position in shares of Medpace in the first quarter worth about $2,666,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.